Holen Sie sich die Stockscreener-App
2.74
4.98%
0.13
Handel nachbörslich:
2.73
-0.01
-0.36%
Schlusskurs vom Vortag:
$2.61
Offen:
$2.72
24-Stunden-Volumen:
1.64M
Relative Volume:
1.10
Marktkapitalisierung:
$403.58M
Einnahmen:
$208.60K
Nettoeinkommen (Verlust:
$-58.59M
KGV:
-2.99
EPS:
-0.9164
Netto-Cashflow:
$-47.11M
1W Leistung:
+15.61%
1M Leistung:
+85.14%
6M Leistung:
+130.25%
1J Leistung:
+48.11%
1-Tages-Spanne:
$2.68
$2.94
1-Wochen-Bereich:
$2.27
$2.94
52-Wochen-Spanne:
$0.7113
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
2.74 | 384.43M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx Nv Aktie (IFRX) Neueste Nachrichten
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
Long term debt to total assets ratio of InflaRx N.V. – HAM:IF0 - TradingView
Discontinued operations of InflaRx N.V. – HAM:IF0 - TradingView
EBIT per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. Cash Flow – HAM:IF0 - TradingView
InflaRx N.V. Balance Sheet – HAM:IF0 - TradingView
InflaRx N.V. Statistics – HAM:IF0 - TradingView
Non-controlling/minority interest of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slo - AD HOC NEWS
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Nigeria
IFRX Technical Analysis | Trend, Signals & Chart Patterns | INFLARX NV (NASDAQ:IFRX) - ChartMill
InflaRx NV stock (NL0012661870): May data from a recent YTD ranking - AD HOC NEWS
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
Raymond James upgrades InflaRx NV (IFRX) - MSN
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential - Investing.com UK
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential By Investing.com - Investing.com South Africa
InflaRx NV Stock (IFRX): Favorable Izicopan Data Released - AD HOC NEWS
TradingKey - TradingKey
TCG Crossover III and Chen Yu disclose 9.8% stake in InflaRx (IFRX) - Stock Titan
InflaRx NV stock (NL0012661870): HC Wainwright raises price target to $8 - AD HOC NEWS
Number of shareholders of InflaRx N.V. – NASDAQ:IFRX - TradingView
Number of shareholders of InflaRx N.V. – TRADEGATE:IF0 - TradingView
InflaRx N.V. Completes $150 Million Underwritten Offering of Ordinary Shares to Advance Pipeline Activities - Moomoo
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026 - The Globe and Mail
IFRX - Finviz
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal DiseasesSlideshow (NASDAQ:IFRX) 2026-05-08 - Seeking Alpha
Transcript : InflaRx N.V.Special Call - marketscreener.com
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - Barchart.com
InflaRx Unveils Izicopan Strategic Shift And $150m Offering - Citeline News & Insights
InflaRx completes $150 million stock offering at $2 per share By Investing.com - Investing.com Australia
InflaRx completes $150 million stock offering at $2 per share - Investing.com
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - The Manila Times
75 million new InflaRx shares raise cash to fund drug pipeline - Stock Titan
Press Release: InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - Moomoo
InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale - Stock Titan
EDGAR Filing Documents for 0001140361-26-019440 - SEC.gov
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq - Insider Monkey
InflaRx (NASDAQ: IFRX) raises $150M via 75M-share offering to fund izicopan - Stock Titan
Form 424B5 InflaRx N.V. - StreetInsider
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx attracts strong investor interest with US share offering turning to kidney - European Biotechnology Magazine
Finanzdaten der Inflarx Nv-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):